PT1294893E - Modificacao do antigenio nuclear de hepatite b - Google Patents

Modificacao do antigenio nuclear de hepatite b

Info

Publication number
PT1294893E
PT1294893E PT01943625T PT01943625T PT1294893E PT 1294893 E PT1294893 E PT 1294893E PT 01943625 T PT01943625 T PT 01943625T PT 01943625 T PT01943625 T PT 01943625T PT 1294893 E PT1294893 E PT 1294893E
Authority
PT
Portugal
Prior art keywords
hepatitis
hbcag
protein
modification
nuclear antigen
Prior art date
Application number
PT01943625T
Other languages
English (en)
Inventor
Page Mark
Li Jing-Li
Pumpens Paul
Borisova Galina
Original Assignee
Ucb Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0015308A external-priority patent/GB0015308D0/en
Priority claimed from GB0024544A external-priority patent/GB0024544D0/en
Application filed by Ucb Pharma Ltd filed Critical Ucb Pharma Ltd
Publication of PT1294893E publication Critical patent/PT1294893E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
PT01943625T 2000-06-22 2001-06-22 Modificacao do antigenio nuclear de hepatite b PT1294893E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0015308A GB0015308D0 (en) 2000-06-22 2000-06-22 Modification of hepatitis B core antigen
GB0024544A GB0024544D0 (en) 2000-10-06 2000-10-06 Modification of hepatitus B core antigen

Publications (1)

Publication Number Publication Date
PT1294893E true PT1294893E (pt) 2006-08-31

Family

ID=26244528

Family Applications (1)

Application Number Title Priority Date Filing Date
PT01943625T PT1294893E (pt) 2000-06-22 2001-06-22 Modificacao do antigenio nuclear de hepatite b

Country Status (11)

Country Link
US (1) US20040054139A1 (pt)
EP (1) EP1294893B1 (pt)
JP (1) JP2004500868A (pt)
AT (1) ATE320493T1 (pt)
AU (2) AU6616301A (pt)
CA (1) CA2413546C (pt)
DE (1) DE60117978T2 (pt)
DK (1) DK1294893T3 (pt)
ES (1) ES2260235T3 (pt)
PT (1) PT1294893E (pt)
WO (1) WO2001098333A2 (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60027581T2 (de) * 1999-10-08 2007-05-10 Celltech Pharma Europe Ltd., Slough Design von immunogene
EA200201077A1 (ru) * 2000-04-07 2003-04-24 Юниверсити Оф Лидз Инновэйшнз Лимитед Коровые антигенные химерные белки гепатита в
US6942866B2 (en) 2000-08-16 2005-09-13 Apovia, Inc. Malaria immunogen and vaccine
CU23002A1 (es) * 2000-12-01 2004-11-18 Ct Ingenieria Genetica Biotech Método de obtención de agregados antigénicos y su uso en formulaciones
US7128911B2 (en) 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
US7094409B2 (en) 2001-01-19 2006-08-22 Cytos Biotechnology Ag Antigen arrays for treatment of allergic eosinophilic diseases
US20040146524A1 (en) * 2002-02-21 2004-07-29 Katelynne Lyons Stabilized immunogenic HBc chimer particles
US7361352B2 (en) 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
US20030202982A1 (en) * 2001-08-15 2003-10-30 Birkett Ashley J. Influenza immunogen and vaccine
AU2002339224B2 (en) 2001-09-14 2008-10-09 Kuros Us Llc Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
US7115266B2 (en) 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
MXPA04002644A (es) 2001-10-05 2004-07-08 Cytos Biotechnology Ag Conjugados que portan un peptido de angiotensina y usos de los mismos.
US7351413B2 (en) * 2002-02-21 2008-04-01 Lorantis, Limited Stabilized HBc chimer particles as immunogens for chronic hepatitis
WO2003072731A2 (en) * 2002-02-21 2003-09-04 Apovia, Inc. STABILIZED HBc CHIMER PARTICLES HAVING MENINGOCCOCAL IMMUNOGENS
JP5084103B2 (ja) 2002-07-18 2012-11-28 サイトス バイオテクノロジー アーゲー ハプテン担体抱合体およびその用法
EP2338510A1 (en) 2002-07-19 2011-06-29 Novartis Pharma AG Vaccine compositions containing amyloid beta1-6 antigen arrays
US7537767B2 (en) 2003-03-26 2009-05-26 Cytis Biotechnology Ag Melan-A- carrier conjugates
EP1605973B1 (en) 2003-03-26 2012-09-26 Cytos Biotechnology AG Packaging of immunostimulatory oligonucleotides into virus-like particles: methods of preparation and uses
EP1651258B1 (en) * 2003-07-30 2014-03-19 Vaccine Research Institute of San Diego Hepatitis virus core proteins as vaccine platforms and methods of use thereof
US7144712B2 (en) * 2003-07-30 2006-12-05 Vaccine Research Institute Of San Diego Human hepatitis B virus core proteins as vaccine platforms and methods of use thereof
US7320795B2 (en) 2003-07-30 2008-01-22 Vaccine Research Institute Of San Diego Rodent hepatitis B virus core proteins as vaccine platforms and methods of use thereof
JP2008504216A (ja) * 2003-12-02 2008-02-14 サイトイミューン サイエンシズ インコーポレイテッド モノクローナル抗体の生成のための方法および組成物
EP1764369A1 (de) 2005-09-16 2007-03-21 Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH Vakzine enthaltend trunkiertes HBV core protein plus Saponin-basierendes Adjuvants
CA2706700A1 (en) * 2007-11-08 2009-05-14 Cytimmune Sciences, Inc. Compositions and methods for generating antibodies
PE20110891A1 (es) 2008-12-09 2011-12-23 Pfizer Vaccines Llc Vacuna de peptido ch3 de ige
CN102596236B (zh) 2009-07-30 2015-06-24 辉瑞疫苗有限责任公司 抗原性Tau肽及其用途
AU2010290931B2 (en) 2009-09-03 2014-02-06 Pfizer Vaccines Llc PCSK9 vaccine
EP2942061A3 (en) 2010-06-07 2016-01-13 Pfizer Vaccines LLC Ige ch3 peptide vaccine
US20140004142A1 (en) 2011-03-02 2014-01-02 Pfizer Inc. Pcsk9 vaccine
EP2698164B1 (en) * 2011-04-15 2018-04-04 Osaka University Dna vaccine
JP6422022B2 (ja) * 2012-08-31 2018-11-14 国立大学法人大阪大学 Ｖｅｇｆ及び／又はアンギオポエチン−２の特異的エピトープを含むｄｎａワクチン
JP6001974B2 (ja) 2012-09-21 2016-10-05 アンジェスＭｇ株式会社 アポリポプロテイン（ａ）の特異的エピトープを含むＤＮＡワクチン
CN104341506A (zh) * 2013-07-30 2015-02-11 复旦大学 一种重组融合蛋白及其用途
US10279019B2 (en) 2014-02-11 2019-05-07 Stc.Unm PCSK9 peptide vaccine conjugated to a Qbeta carrier and methods of using the same
WO2015133467A1 (ja) * 2014-03-06 2015-09-11 株式会社シノテスト Ｃ型肝炎ウイルスのワクチン及び診断に用いるためのＨＢｃ／ＨＣＶ Ｅ２ペプチドキメラタンパク質
CA3092935A1 (en) * 2018-03-06 2019-09-12 Precigen, Inc. Hepatitis b vaccines and uses of the same
CN114729010A (zh) * 2019-08-29 2022-07-08 维尔生物科技有限公司 乙型肝炎病毒疫苗
CR20220129A (es) 2019-09-30 2022-05-06 Gilead Sciences Inc Vacunas para vhb y métodos de tratamiento de vhb

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ235315A (en) * 1989-09-19 1991-09-25 Wellcome Found Chimaeric hepadnavirus core antigen proteins and their construction
DK1119630T3 (da) * 1998-11-05 2006-05-15 Powderject Vaccines Inc Nukleinsyrekonstruktioner til genetisk immunisering

Also Published As

Publication number Publication date
DK1294893T3 (da) 2006-07-03
EP1294893B1 (en) 2006-03-15
DE60117978T2 (de) 2006-11-02
ES2260235T3 (es) 2006-11-01
ATE320493T1 (de) 2006-04-15
AU6616301A (en) 2002-01-02
WO2001098333A2 (en) 2001-12-27
CA2413546A1 (en) 2001-12-27
WO2001098333A3 (en) 2002-03-28
JP2004500868A (ja) 2004-01-15
AU2001266163B2 (en) 2006-07-13
DE60117978D1 (de) 2006-05-11
CA2413546C (en) 2011-06-14
EP1294893A2 (en) 2003-03-26
US20040054139A1 (en) 2004-03-18

Similar Documents

Publication Publication Date Title
PT1294893E (pt) Modificacao do antigenio nuclear de hepatite b
BG98523A (en) Hla-limited cytotoxic t-lymphocytic (ctl) epitopes of the virus of hepatite b
DE60039715D1 (de) Hcv-impfstoff zusammensetzungen
NZ545048A (en) Chimeric antigens for breaking host tolerance to foreign antigens
ES2109921T3 (es) Nuevos antigenos y procedimientos para su preparacion.
EA200300129A1 (ru) Очистка антигенов вируса гепатита b (hbv) для применения в вакцинах
DK1362109T3 (da) Rekombinante oligomere protein-komplekser med foröget immunogent potentiale
EA200201077A1 (ru) Коровые антигенные химерные белки гепатита в
DK1283887T3 (da) Kimære Arterivirus-lignende partikler
ATE323758T1 (de) Attenuierte lebendimpfstoffe
AP2002002685A0 (en) Use of flavivirus for the expression of protein epitpoes and development of new live attenuated vaccine virus to immune against flavivirus and other infectious agents
DK1035133T3 (da) Fusionsproteiner, der omfatter bærere, som kan inducere et dobbelt immunrespons
SE9903534L (sv) Bärare innehållande ett huvudkapsidprotein L1 från humant papillomavirus samt dess användning
ATE283066T1 (de) Impfstoff enthaltend zytokin-induzierte heat shock proteine (hsp)
HK1052368A1 (zh) 具有源於肝炎e病毒orf2的n末端部分及一抗原多肽加工的編碼成份的核酸結構
ATE409705T1 (de) Pre-s-protein von hepatitis-b-virus (hbv) als adjuvans und komponente eines hbv-impfstoffs
HUP0003511A2 (hu) Hepatitisz-B-vírus polipeptidek
WO2001092311A3 (fr) Bibliotheques peptidiques combinatoires convergentes et leur applicaton a la vaccination contre le virus de l'hepatite c
SE0002498D0 (sv) Papillomavirus vaccine
AU4394101A (en) A nucleic acid construct encoding a processing component derived from the n-terminal region of the hepatitis virus ORF2, and an antigenic polypeptide
ATE374040T1 (de) Nukleoprotein des toscanavirus